Premium
Successful treatment of chronic hepatitis C infection with crushed elbasvir/grazoprevir administered via a percutaneous endoscopic gastrostomy tube
Author(s) -
Yap J. E.,
Jaiswal P.,
Ton L.,
Szynkarek R.,
Attar B. M.,
Gandhi S.
Publication year - 2018
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12713
Subject(s) - medicine , percutaneous endoscopic gastrostomy , regimen , population , surgery , gastroenterology , peg ratio , environmental health , finance , economics
Summary What is known and objective Elbasvir/grazoprevir is an all‐oral regimen approved for patients with hepatitis C virus ( HCV ) genotypes 1 and 4, and in renal insufficiency. However, to date, no data exist on the efficacy of this regimen when it is crushed and administered through a percutaneous endoscopic gastrostomy ( PEG ) tube. Here, we illustrate the case of a 63‐year‐old man who is the only known patient with HCV infection in the English literature to have successfully achieved a sustained viral response ( SVR ) when elbasvir/grazoprevir oral combination was administered through a PEG tube. Case summary A 63‐year‐old man with worsening HCV ‐associated membranoproliferative glomerulonephritis was referred to the gastroenterology clinic for prompt HCV treatment. He had history of high‐grade mucoepidermoid carcinoma of the parotid status post‐resection and was expected to develop severe mucositis and dysphagia during radiation precluding typical oral therapy of his HCV . He received a PEG tube for nutrition and underwent a 16 week course of crushed Elbasvir/Grazoprevir for HCV treatment through the PEG . At the end of the therapy he achieved SVR and his kidney function also improved. What is new and conclusion We present the first known clinical case of a non‐cirrhotic patient with HCV genotype 1A with HCV ‐related MPGN treated successfully with crushed Elbasvir/Grazoprevir administered through a PEG tube. With the prevalence of PEG tube insertion and HCV on a rise, we expect these 2 population cohorts to intersect in the future. Our report may serve as a guidance in such clinical scenario.